LONA - Athira Pharma, Inc.
5.3
-0.070 -1.321%
Share volume: 12,517
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.19%
PREVIOUS CLOSE
CHG
CHG%
$5.37
-0.07
-0.01%
Fundamental analysis
33%
Profitability
35%
Dept financing
22%
Liquidity
50%
Performance
30%
Performance
5 Days
-7.34%
1 Month
18.83%
3 Months
36.60%
6 Months
1,276.62%
1 Year
1,451.98%
2 Year
27.71%
Key data
Stock price
$5.30
DAY RANGE
$5.11 - $5.56
52 WEEK RANGE
$0.22 - $8.36
52 WEEK CHANGE
$1,598.17
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
Company detail
CEO: Mark J. Litton
Region: US
Website: athira.com
Employees: 40
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: athira.com
Employees: 40
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in Phase 3 and ACT-AD clinical trials for the treatment of Alzheimer's disease.
Recent news